Meningococcal factor H binding protein fHbpd184 polymorphism influences clinical course of meningococcal meningitis

Jurgen R Piet1, Matthijs C Brouwer, Rachel Exley

  • 1Department of Neurology, Center of Infection and Immunity Amsterdam-CINIMA, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Plos One
|October 31, 2012
PubMed

Insights

Factor H Binding protein (fHbp) variants impact meningococcal disease. The fHbp(D184) variant is linked to increased risk of septic shock and unfavorable outcomes in patients with meningococcal meningitis.

Area of Science:

  • Microbiology
  • Immunology
  • Genetics

Background:

  • Factor H Binding protein (fHbp) is a key meningococcal virulence factor that helps bacteria evade the complement system.
  • fHbp is a primary target for meningococcal vaccines.
  • Structural studies revealed interactions between fHbp and complement factor H (fH), involving specific amino acid residues like E(283) and E(304).

Purpose of the Study:

  • To investigate the impact of fHbp variants on the severity and outcomes of meningococcal meningitis.
  • To analyze the correlation between specific fHbp genetic variations and clinical manifestations.
  • To understand how fHbp polymorphisms influence the interaction with human factor H.

Main Methods:

  • Sequencing of fHbp from 254 meningococcal isolates from adult patients with meningitis.
  • Analysis of clinical data including disease severity and patient outcomes.
  • Assessment of fHbp-fH binding affinity using Surface Plasmon Resonance for specific variants (e.g., fHbp(K184) and fHbp(D184)).

Main Results:

  • fHbp subfamily A isolates showed a substitution of E304 with T304.
  • Patients infected with meningococci expressing fHbp subfamily A had a lower proportion of unfavorable outcomes compared to subfamily B.
  • The fHbp(D184) variant was significantly associated with a higher likelihood of developing septic shock (26% vs. 9%) and unfavorable outcomes (21% vs. 10%) in patients.

Conclusions:

  • Specific fHbp variants, particularly fHbp(D184), are associated with increased disease severity in meningococcal meningitis.
  • The identified fHbp variants influence the interaction with factor H, potentially affecting complement evasion.
  • Understanding these fHbp-host interactions is crucial for developing effective vaccines and treatments against meningococcal disease.

Related Concept Videos

Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...